Acadia Wins Patent Ruling Over Aurobindo’s Nuplazid Copies (2)

Aurobindo Pharma Ltd.’s proposed copies of Acadia Pharmaceuticals Inc.’s Nuplazid capsules infringe a patent for the Parkinson’s disease drug that won’t expire for more than 13 years, a federal judge ruled Friday.

Acadia convinced Judge Gregory B. Williams that Aurobindo’s generic pimavanserin capsules infringe US Patent No. 11,452,721 and Aurobindo failed to prove the patent’s claims are invalid, according to an order in the US District Court for the District of Delaware. Williams issued an opinion explaining his reasoning under seal, which comes after a December bench trial.

The ‘721 and three related patents expire in August 2038, the latest ...